Ketamine Therapy Among Patients With Treatment-resistant Depression: A Randomised, Double-blind, Placebo-controlled Trial
Funder
National Health and Medical Research Council
Funding Amount
$2,069,382.00
Summary
In the last decade, there have been reports of powerful antidepressant effects after a single injection of anaesthetic ketamine, with dramatic (though shortlasting) effects within 24 hours. This will be the first controlled study to test whether a course of repeated ketamine treatments, given over 4 weeks, is effective and safe in treating depression.
Plasma Exchange And Glucocorticoids In Anti-neutrophil Cytoplasm Antibody Associated Systemic Vasculitis: A Randomised Controlled Trial (PEXIVAS Australia)
Funder
National Health and Medical Research Council
Funding Amount
$420,110.00
Summary
ANCA-associated vasculitis is a life-threatening disease. The PEXIVAS trial will investigate whether plasma exchange, in addition to immunosuppressive therapy and glucocorticoids, will reduce death and the development of severe kidney failure due to this disease. Additionally, the project will also look at whether using a reduced dose of glucocorticoids is just as effective as larger doses in lessening the infectious complications of treatment.
Community-wide Active Case Finding For Tuberculosis
Funder
National Health and Medical Research Council
Funding Amount
$3,422,325.00
Summary
During 2010, 8.8 million people developed TB and 1.45 million people died due to the disease. In this project, which will be conducted in Vietnam, one of the countries in our region with a particularly high prevalence of TB, we will test a new form of an old intervention: community-wide screening for TB, not with x-rays but by testing sputum. If the project is successful it has the potential to lead to a giant leap forward towards the elimination of TB as a global health problem.
Gene Expression Profiling In Critically Ill Patients With Septic Shock: The ADRENAL-GEPS Study
Funder
National Health and Medical Research Council
Funding Amount
$863,304.00
Summary
Sepsis refers to a whole body inflammation caused by severe infection. Approximately one in three adults admitted with septic shock die within 28 days and it is unclear whether treatment with anti-inflammatory drugs is beneficial in terms of patient survival. The aim of this study is to develop a clinical test based on gene activity that can be used to predict patient survival and also determine what the best treatment might be for individual patients.
Improving Skin Cancer Prevention: Motivating Preventive Behaviours Using Knowledge Of Personalised Genomic Risk Of Melanoma
Funder
National Health and Medical Research Council
Funding Amount
$1,041,720.00
Summary
The aim of our study is to evaluate whether we can improve the Australian public’s skin cancer prevention behaviours, particularly reducing exposure to ultraviolet (UV) radiation, by giving personalised information about melanoma genetic risk. We will also explore the psycho-social, ethical, and economic implications of receiving this information. The results of our study are likely to influence the future of skin cancer prevention in Australia.
The Effectiveness Of A Comprehensive ‘universal’ And ‘targeted’ Intervention To Prevent Substance Use And Related Harms In Adolescents: The CAP Project
Funder
National Health and Medical Research Council
Funding Amount
$755,906.00
Summary
Alcohol and other drug use are common amongst Australian adolescents and the disability associated with this use is considerable. Prevention is clearly needed, yet we have few models of well implemented prevention programs that are effective in maximisising prevention outcomes.The current proposal addresses this gap by evaluating a novel approach to preventing substance use and related harms in adolescents by combining effective 'universal' and 'targeted' school-based prevention programs in a su ....Alcohol and other drug use are common amongst Australian adolescents and the disability associated with this use is considerable. Prevention is clearly needed, yet we have few models of well implemented prevention programs that are effective in maximisising prevention outcomes.The current proposal addresses this gap by evaluating a novel approach to preventing substance use and related harms in adolescents by combining effective 'universal' and 'targeted' school-based prevention programs in a sustainable delivery platform.Read moreRead less
Treatment Of Invasively Ventilated Adults With Early Activity And Mobilisation
Funder
National Health and Medical Research Council
Funding Amount
$1,467,137.00
Summary
The sickest patients in intensive care units (ICUs) receive prolonged, invasive support for their breathing. This is currently managed with complete bed rest, and results in severe muscle weakness, increased duration of hospital stay and poor recovery. We have found that early activity and mobilisation during invasive breathing support is safe and may improve survival and recovery. We will test early activity and mobilisation in a large randomised controlled trial of 750 ICU patients.
The N-ICE Trial: A Randomised Controlled Trial Of The Safety And Efficacy Of N-Acetyl Cysteine (NAC) As A Pharmacotherapy For Methamphetamine (“ice”) Dependence
Funder
National Health and Medical Research Council
Funding Amount
$1,551,368.00
Summary
Crystalline methamphetamine (aka ‘ice’) is a significant public health concern in Australia and globally. Currently there are no approved medications to treat methamphetamine dependence. We will trial tN-acetyl-cysteine (NAC) as a medications for methamphetamine dependence.
A Randomised Trial Of A Clinical Prediction Tool For Targeting Depression Care (Target-D)
Funder
National Health and Medical Research Council
Funding Amount
$944,774.00
Summary
The Target-D Study uses a novel clinical prediction tool to test a new approach to depression care in general practice based upon sub-grouping patients into low, medium and high risk of ongoing depression. Participants will be randomly allocated to targeted treatments based upon their risk profile or to usual general practice care. We will measure whether the new approach results in greater improvements in depressive symptoms, quality of life and functioning and whether there are cost benefits.
N-Acetyl Cysteine In Schizophrenia Resistant To Clozapine: A Double-Blind Randomised Placebo-Controlled Trial Targeting Negative Symptoms
Funder
National Health and Medical Research Council
Funding Amount
$981,789.00
Summary
Many patients with schizophrenia remain treatment resistant even after “last resort” medications like clozapine. This proposal will conduct a novel multi-site randomised placebo controlled trial of adjunctive N-acetyl cysteine in patients with clozapine resistant schizophrenia. Treatment efficacy will be examined at 8, 26 and 52 weeks.